title: Effects of time required for reperfusion (thrombolysis or angioplasty, or both) and location of acute myocardial infarction on left ventricular functional reserve capacity several months later.
abstract: The purpose of this study was to determine whether reperfusion of acute myocardial infarction (AMI) by recombinant tissue-type plasminogen activator (rt-PA) or percutaneous transluminal coronary angioplasty, or both, would improve left ventricular (LV) function when it is measured several months later at rest or maximal bicycle exercise, or both. Radionuclide angiography was performed in 44 patients 5 months (range 6 weeks to 9 months) after AMI to assess function, and tomographic myocardial thallium-201 imaging was performed at maximal exercise and delayed rest to determine whether there was any evidence of myocardial ischemia. As expected, no patient had chest pain or redistribution of a thallium defect during the exercise test, because patients had undergone angioplasty (n = 28) or coronary bypass graft surgery (n = 5) where clinically indicated for revascularization. The LV ejection fraction was plotted as a function of the time elapsed between the onset of chest pain and the time when coronary angiography confirmed patency of the infarct-related artery (achieved in 91% of 44 patients by rt-PA [n = 31] or percutaneous transluminal coronary angioplasty [n = 9] ). Functional responses differed markedly between patients with anterior (n = 20) versus inferior (n = 24) wall AMI. LV ejection fraction during exercise correlated with time to reperfusion in patients with an anterior wall AMI (r = -0.58; standard error of the estimate = 11.9%; p less than 0.02) but not in patients with an inferior AMI (r = 0.10; standard error of the estimate = 13.1%; difference not significant.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Carlyle Fraser Heart Center, Crawford Long Hospital, Emory University, Atlanta, Georgia 30365.
authors.forename: T
authors.initials: T
authors.lastname: Little
authors.forename: M
authors.initials: M
authors.lastname: Crenshaw
authors.forename: H A
authors.initials: HA
authors.lastname: Liberman
authors.forename: L L
authors.initials: LL
authors.lastname: Battey
authors.forename: R
authors.initials: R
authors.lastname: Warner
authors.forename: A L
authors.initials: AL
authors.lastname: Churchwell
authors.forename: R L
authors.initials: RL
authors.lastname: Eisner
authors.forename: D C
authors.initials: DC
authors.lastname: Morris
authors.forename: R E
authors.initials: RE
authors.lastname: Patterson
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D015637:Gated Blood-Pool Imaging; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000502:physiology; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy*; D015425:Myocardial Reperfusion; D010919:Placebos; D013318:Stroke Volume / Q000502:physiology; D013794:Thallium Radioisotopes; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*; D014055:Tomography, Emission-Computed; D016277:Ventricular Function, Left / Q000502:physiology*
chemical_list: D010919:Placebos; D013794:Thallium Radioisotopes; D010959:Tissue Plasminogen Activator